Glycyrrhizic Acid Protects Glomerular Podocytes Induced by High Glucose by Modulating SNARK/AMPK Signaling Pathway.
AMPK
SNARK
diabetic nephropathy
glomerular fibrosis
glycyrrhizic acid
podocyte
Journal
Current medical science
ISSN: 2523-899X
Titre abrégé: Curr Med Sci
Pays: China
ID NLM: 101729993
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
02
12
2022
accepted:
19
04
2023
medline:
23
8
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
ppublish
Résumé
Diabetic nephropathy is one of the most important microvascular complications of diabetes, which mainly refers to glomerular capillary sclerosis. Podocytes are an important part of glomerular capillaries. Previous clinical and basic studies have shown that fibrosis is the main factor of diabetic nephropathy. This study aimed to assess the protective mechanism of glycyrrhizic acid (GA) on glomerular podocytes induced by high glucose as we hypothesized that GA may have antifibrotic and anti-inflammatory effects on podocytes through regulation of the adenosine 5'-monophosphate-activated protein kinase (AMPK)/sucrose nonfermenting AMPK-related kinase (SNARK) signaling pathway. SNARK siRNA was used to transfect podocytes. Real-time quantitative polymerase chain reaction and immunofluorescence staining assays were used for molecular and pathological analysis. The expression levels of key pathway proteins (including TGF-β1, α-SMA, SITR1, AMPKα, LKB1, PGC-1α, NF-κB, IL-6, and TNF-α) were verified by Western blotting. The expression of inflammatory factors in podocytes was detected by ELISA. We demonstrated that GA decreased the expression of podocyte fibrosis signaling pathway-related factors by upregulating the AMPK pathway and its related factors. However, after transfection of podocytes with SNARK siRNA, there was an increased expression of fibrosis-related factors and inflammation-related factors. GA can protect podocytes and alleviate fibrosis and inflammation induced by high glucose, which is related to the AMPK signaling pathway. Meanwhile, knockdown of SNARK protein can inhibit the AMPK signaling pathway, aggravate fibrosis, and increase inflammation.
Identifiants
pubmed: 37450070
doi: 10.1007/s11596-023-2765-y
pii: 10.1007/s11596-023-2765-y
doi:
Substances chimiques
AMP-Activated Protein Kinases
EC 2.7.11.31
Glucose
IY9XDZ35W2
Glycyrrhizic Acid
6FO62043WK
RNA, Small Interfering
0
SNARK protein, mouse
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
696-707Informations de copyright
© 2023. Huazhong University of Science and Technology.
Références
Tsoutsouki J, Wunna W, Chowdhury A, et al. Advances in the management of diabetes: therapies for type 2 diabetes. Postgrad Med J, 2020,96(1140):610–618
pubmed: 32467106
doi: 10.1136/postgradmedj-2019-137404
Libianto R, Davis TM, Ekinci EI, et al. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes. Med J Aust, 2020,212(3):133–139
pubmed: 31910303
doi: 10.5694/mja2.50472
Horikoshi S, Fukuda N, Tsunemi A, et al. Contribution of TGF-beta1 and Effects of Gene Silencer Pyrrole-Imidazole Polyamides Targeting TGF-beta1 in Diabetic Nephropathy. Molecules, 2020,25(4):950
pubmed: 32093382
pmcid: 7070568
doi: 10.3390/molecules25040950
Chung JY, Chan MK, Li JS, et al. TGF-beta Signaling: From Tissue Fibrosis to Tumor Microenvironment. Int J Mol Sci, 2021,22(14):7575
pubmed: 34299192
pmcid: 8303588
doi: 10.3390/ijms22147575
Wang Y, Jia L, Hu Z, et al. AMP-activated protein kinase/myocardin-related transcription factor-A signaling regulates fibroblast activation and renal fibrosis. Kidney Int, 2018,93(1):81–94
pubmed: 28739141
doi: 10.1016/j.kint.2017.04.033
Coughlan KA, Valentine RJ, Ruderman NB, et al. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes, 2014,7:241–253
pubmed: 25018645
pmcid: 4075959
Li NS, Zou JR, Lin H, et al. LKB1/AMPK inhibits TGF-beta1 production and the TGF-beta signaling pathway in breast cancer cells. Tumour Biol, 2016,37(6):8249–8258
pubmed: 26718214
doi: 10.1007/s13277-015-4639-9
Lefebvre DL, Bai Y, Shahmolky N, et al. Identification and characterization of a novel sucrose-non-fermenting protein kinase/AMP-activated protein kinase-related protein kinase, SNARK. Biochem J, 2001,355(2):297–305
pubmed: 11284715
pmcid: 1221739
doi: 10.1042/bj3550297
Goto K, Kato N, Chung RT, et al. Anti-hepatocellular carcinoma properties of the anti-alcoholism drug disulfiram discovered to enzymatically inhibit the AMPK-related kinase SNARK in vitro. Oncotarget, 2016,7(46):74987–74999
pubmed: 27602492
pmcid: 5342717
doi: 10.18632/oncotarget.11820
Courchet J, Lewis TL, Lee S, et al. Terminal axon branching is regulated by the LKB1-NUAK1 kinase pathway via presynaptic mitochondrial capture. Cell, 2013,153(7):1510–1525
pubmed: 23791179
pmcid: 3729210
doi: 10.1016/j.cell.2013.05.021
Sun XL, Lessard SJ, An D, et al. Sucrose nonfermenting AMPK-related kinase (SNARK) regulates exercise-stimulated and ischemia-stimulated glucose transport in the heart. J Cell Biochem, 2019,120(1):685–696
pubmed: 30256437
doi: 10.1002/jcb.27425
Liu B, Gan X, Zhao Y, et al. Inhibition of HMGB1 reduced high glucose-induced BMSCs apoptosis via activation of AMPK and regulation of mitochondrial functions. J Physiol Biochem, 2021,77(2):227–235
pubmed: 33635525
doi: 10.1007/s13105-021-00784-2
Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol, 2010,21(2):212–222
pubmed: 20019167
doi: 10.1681/ASN.2008121226
Tang Q, Cao Y, Xiong W, et al. Glycyrrhizic acid exerts protective effects against hypoxia/reoxygenation-induced human coronary artery endothelial cell damage by regulating mitochondria. Exp Ther Med, 2020,20(1):335–342
pubmed: 32509013
pmcid: 7271712
Wang YJ, Wang Z, Zhao TQ, et al. Effect of Glycyrrhizic Acid on High Glucose Induced Podocyte Injury in Mice. J Ningxia Med Univ (Chinese), 2022,44(03):267–271
Rajab BS, Albukhari TA, Khan AA, et al. Antioxidative and Anti-Inflammatory Protective Effects of beta-Caryophyllene against Amikacin-Induced Nephrotoxicity in Rat by Regulating the Nrf2/AMPK/AKT and NF-kappaB/TGF-beta/KIM-1 Molecular Pathways. Oxid Med Cell Longev, 2022,2022:4212331
pubmed: 36062191
pmcid: 9439917
doi: 10.1155/2022/4212331
Zhang YL, Li PB, Han X, et al. Blockage of Fibronectin 1 Ameliorates Myocardial Ischemia/Reperfusion Injury in Association with Activation of AMP-LKB1-AMPK Signaling Pathway. Oxid Med Cell Longev, 2022,2022:6196173
pubmed: 35602095
pmcid: 9119763
Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum. Am J Kidney Dis, 2018,71(6):884–895
pubmed: 29398179
doi: 10.1053/j.ajkd.2017.10.026
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med, 2021,384(2):129–139
pubmed: 33200891
doi: 10.1056/NEJMoa2030186
Chen J, Chen JK, Harris RC, et al. EGF receptor deletion in podocytes attenuates diabetic nephropathy. J Am Soc Nephrol, 2015,26(5):1115–1125
pubmed: 25185988
doi: 10.1681/ASN.2014020192
Wu M, Yang Z, Zhang C, et al. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy. Metabolism, 2021,118:154748
pubmed: 33675822
doi: 10.1016/j.metabol.2021.154748
Song S, Qiu D, Shi Y, et al. Thioredoxin-interacting protein deficiency alleviates phenotypic alterations of podocytes via inhibition of mTOR activation in diabetic nephropathy. J Cell Physiol, 2019,234(9):16485–16502
pubmed: 30746698
doi: 10.1002/jcp.28317
Gil CL, Hooker E, Larrivee B, et al. Diabetic Kidney Disease, Endothelial Damage, and Podocyte-Endothelial Crosstalk. Kidney Med, 2020,3(1):105–115
pubmed: 33604542
pmcid: 7873832
doi: 10.1016/j.xkme.2020.10.005
Guo Q, Zhong W, Duan A, et al. Protective or deleterious role of Wnt/beta-catenin signaling in diabetic nephropathy: An unresolved issue. Pharmacol Res, 2019,144:151–157
pubmed: 30935943
doi: 10.1016/j.phrs.2019.03.022
Chaudhuri A, Ghanim H, Arora P, et al. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes Metab, 2022,24(3):365–376
pubmed: 34779091
doi: 10.1111/dom.14601
Grahammer F, Schell C, Huber TB, et al. The podocyte slit diaphragm—from a thin grey line to a complex signalling hub. Nat Rev Nephrol, 2013,9(10):587–598
pubmed: 23999399
doi: 10.1038/nrneph.2013.169
Wang D, Sant S, Ferrell N, et al. A Biomimetic In Vitro Model of the Kidney Filtration Barrier Using Tissue-Derived Glomerular Basement Membrane. Adv Healthc Mater, 2021,10(16):e2002275
pubmed: 34218528
doi: 10.1002/adhm.202002275
Yoshida S, Wei X, Zhang G, et al. Endoplasmic reticulum-associated degradation is required for nephrin maturation and kidney glomerular filtration function. J Clin Invest, 2021,131(7):e143988
pubmed: 33591954
pmcid: 8011890
doi: 10.1172/JCI143988
Lu Q, Hou Q, Cao K, et al. Complement factor B in high glucose-induced podocyte injury and diabetic kidney disease. JCI Insight, 2021,6(19):e147716
pubmed: 34622800
pmcid: 8525650
doi: 10.1172/jci.insight.147716
Lin CL, Hsu YC, Huang YT, et al. A KDM6A-KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction. EMBO Mol Med, 2019,11(5):e9828
pubmed: 30948420
pmcid: 6505577
doi: 10.15252/emmm.201809828
Sheng L, Zhuang S. New Insights Into the Role and Mechanism of Partial Epithelial-Mesenchymal Transition in Kidney Fibrosis. Front Physiol, 2020,11:569322
pubmed: 33041867
pmcid: 7522479
doi: 10.3389/fphys.2020.569322
Li L, Feng Y, Zhang J, et al. Microtubule associated protein 4 phosphorylation-induced epithelial-to-mesenchymal transition of podocyte leads to proteinuria in diabetic nephropathy. Cell Commun Signal, 2022,20(1):115
pubmed: 35902952
pmcid: 9331595
doi: 10.1186/s12964-022-00883-7
Cherney DZI, Dekkers CCJ, Barbour SJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol, 2020,8(7):582–593
pubmed: 32559474
doi: 10.1016/S2213-8587(20)30162-5
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med, 2019,380(24):2295–2306
pubmed: 30990260
doi: 10.1056/NEJMoa1811744
Gujarati NA, Leonardo AR, Vasquez JM, et al. Loss of Functional SCO2 Attenuates Oxidative Stress in Diabetic Kidney Disease. Diabetes, 2021,db210316
Galvan DL, Long J, Green N, et al. Drp1S600 phosphorylation regulates mitochondrial fission and progression of nephropathy in diabetic mice. J Clin Invest, 2019,129(7):2807–2823
pubmed: 31063459
pmcid: 6597204
doi: 10.1172/JCI127277
Sun W, Wang Y, Zheng Y, et al. The Emerging Role of Sestrin2 in Cell Metabolism, and Cardiovascular and Age-Related Diseases. Aging Dis, 2020,11(1):154–163
pubmed: 32010489
pmcid: 6961765
doi: 10.14336/AD.2019.0320
Juszczak F, Caron N, Mathew AV, et al. Critical Role for AMPK in Metabolic Disease-Induced Chronic Kidney Disease. Int J Mol Sci, 2020,21(21):7994
pubmed: 33121167
pmcid: 7663488
doi: 10.3390/ijms21217994
Song S, Shi C, Bian Y, et al. Sestrin2 remedies podocyte injury via orchestrating TSP-1/TGF-beta1/Smad3 axis in diabetic kidney disease. Cell Death Dis, 2022,13(7):663
pubmed: 35908070
pmcid: 9338940
doi: 10.1038/s41419-022-05120-0
Wu M, Chen G, Li YP, et al. TGF-beta and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res, 2016,4:16009
pubmed: 27563484
pmcid: 4985055
doi: 10.1038/boneres.2016.9
Zhang YD, Zhao SC, Zhu ZS, et al. Cx43- and Smad-Mediated TGF-beta/ BMP Signaling Pathway Promotes Cartilage Differentiation of Bone Marrow Mesenchymal Stem Cells and Inhibits Osteoblast Differentiation. Cell Physiol Biochem, 2017,42(4):1277–1293
pubmed: 28697500
doi: 10.1159/000478957
Li J, Li N, Yan S, et al. Melatonin attenuates renal fibrosis in diabetic mice by activating the AMPK/PGC1alpha signaling pathway and rescuing mitochondrial function. Mol Med Rep, 2019,19(2):1318–1330
pubmed: 30535482
Kim H, Moon SY, Kim JS, et al. Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis. Am J Physiol Renal Physiol, 2015,308(3):F226–F236
pubmed: 25428127
doi: 10.1152/ajprenal.00495.2014
Gamad N, Malik S, Suchal K, et al. Metformin alleviates bleomycin-induced pulmonary fibrosis in rats: Pharmacological effects and molecular mechanisms. Biomed Pharmacother, 2018,97:1544–1553
pubmed: 29793317
doi: 10.1016/j.biopha.2017.11.101
Wang L, Tian Y, Shang Z, et al. Metformin attenuates the epithelial-mesenchymal transition of lens epithelial cells through the AMPK/TGF-beta/Smad2/3 signalling pathway. Exp Eye Res, 2021,212:108763
pubmed: 34517004
doi: 10.1016/j.exer.2021.108763
van de Vis RAJ, Moustakas A, van der Heide LP, et al. NUAK1 and NUAK2 Fine-Tune TGF-beta Signaling. Cancers (Basel), 2021,13(13):3377
pubmed: 34282782
doi: 10.3390/cancers13133377
Kolliopoulos C, Raja E, Razmara M, et al. Transforming growth factor beta (TGFbeta) induces NUAK kinase expression to fine-tune its signaling output. J Biol Chem, 2019,294(11):4119–4136
pubmed: 30622137
pmcid: 6422081
doi: 10.1074/jbc.RA118.004984
Feng X, Chen X, Zaeem M, et al. Sesamol Attenuates Neuroinflammation by Regulating the AMPK/SIRT1/NF-kappaB Signaling Pathway after Spinal Cord Injury in Mice. Oxid Med Cell Longev, 2022,2022:8010670
pubmed: 35035666
pmcid: 8758308
doi: 10.1155/2022/8010670
Xu T, Wang S, Li X, et al. Lithium chloride represses abdominal aortic aneurysm via regulating GSK3beta/SIRT1/NF-kappaB signaling pathway. Free Radic Biol Med, 2021,166:1–10
pubmed: 33588051
doi: 10.1016/j.freeradbiomed.2021.02.007
Gao C, Fei X, Wang M, et al. Cardamomin protects from diabetes-induced kidney damage through modulating PI3K/AKT and JAK/STAT signaling pathways in rats. Int Immunopharmacol, 2022,107:108610
pubmed: 35219163
doi: 10.1016/j.intimp.2022.108610
Sun HJ, Xiong SP, Cao X, et al. Polysulfide-mediated sulfhydration of SIRT1 prevents diabetic nephropathy by suppressing phosphorylation and acetylation of p65 NF-kappaB and STAT3. Redox Biol, 2021,38:101813
pubmed: 33279869
doi: 10.1016/j.redox.2020.101813
Kimura Y, Yanagida T, Onda A, et al. Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation. Arterioscler Thromb Vasc Biol, 2020,40(3):570–582
pubmed: 31996020
doi: 10.1161/ATVBAHA.119.313224
Kato K, Tokuda H, Matsushima-Nishiwaki R, et al. AMPK limits IL-1-stimulated IL-6 synthesis in osteoblasts: involvement of IkappaB/NF-kappaB pathway. Cell Signal, 2012,24(8):1706–1712
pubmed: 22560875
doi: 10.1016/j.cellsig.2012.04.012
Oh H, Park SH, Kang MK, et al. Asaronic Acid Attenuates Macrophage Activation toward M1 Phenotype through Inhibition of NF-kappaB Pathway and JAK-STAT Signaling in Glucose-Loaded Murine Macrophages. J Agric Food Chem, 2019,67(36):10069–10078
pubmed: 31422663
doi: 10.1021/acs.jafc.9b03926
Cao XJ, Wu R, Qian HY, et al. Metformin attenuates diabetic neuropathic pain via AMPK/NF-kappaB signaling pathway in dorsal root ganglion of diabetic rats. Brain Res, 2021,1772:147663
pubmed: 34555415
doi: 10.1016/j.brainres.2021.147663
Li F, Chen Y, Li Y, et al. Geniposide alleviates diabetic nephropathy of mice through AMPK/SIRT1/NF-kappaB pathway. Eur J Pharmacol, 2020,886:173449
pubmed: 32758570
doi: 10.1016/j.ejphar.2020.173449
Mancini SJ, White AD, Bijland S, et al. Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation. Mol Cell Endocrinol, 2017,440:44–56
pubmed: 27840174
pmcid: 5228585
doi: 10.1016/j.mce.2016.11.010
Huang W, Shang WL, Wang HD, et al. Sirt1 overexpression protects murine osteoblasts against TNF-alpha-induced injury in vitro by suppressing the NF-kappaB signaling pathway. Acta Pharmacol Sin, 2012,33(5):668–674
pubmed: 22447223
pmcid: 4010359
doi: 10.1038/aps.2011.189
Lee IY, Lim JM, Cho H, et al. MST1 Negatively Regulates TNFalpha-Induced NF-kappaB Signaling through Modulating LUBAC Activity. Mol Cell, 2019,73(6):1138–1149.e6
pubmed: 30901564
doi: 10.1016/j.molcel.2019.01.022
Li HN, Yang QQ, Wang WT, et al. Red nucleus IL-33 facilitates the early development of mononeuropathic pain in male rats by inducing TNF-alpha through activating ERK, p38 MAPK, and JAK2/STAT3. J Neuroinflammation, 2021,18(1):150
pubmed: 34225736
pmcid: 8258957
doi: 10.1186/s12974-021-02198-9
Fadaei R, Bagheri N, Heidarian E, et al. Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNF-alpha and IL-6. Cytokine, 2020,125:154832
pubmed: 31479874
doi: 10.1016/j.cyto.2019.154832
Pang R, Gu D. Triptolide Improves Renal Injury in Diabetic Nephropathy Rats through TGF-beta1/Smads Signal Pathway. Endocr Metab Immune Disord Drug Targets, 2021,21(10):1905–1911
pubmed: 34530721
doi: 10.2174/1871530320666201208110209
Zitman-Gal T, Einbinder Y, Ohana M, et al. Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells. J Diabetes, 2019,11(8):656–664
pubmed: 30575282
doi: 10.1111/1753-0407.12891
Johnson DE, O’Keefe RA, Grandis JR, et al. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol, 2018,15(4):234–248
pubmed: 29405201
pmcid: 5858971
doi: 10.1038/nrclinonc.2018.8